Biotech Values

[turtlepower]

Its possible that MRK see's fewer events of anemia in the ongoing PIII Boceprevir trials and views the trial due to complete in 2011 in a different light than it did last year after unveiling the PII results which showed anemia in 50% of the patients. Or they are taking a calculated risk in order to not give away too much market share. Then again they may decide to wait till 2011 if anemia is common in the ongoing trials because the FDA asked them to. So to summarize I think they are serious about filing in 2010 provided anemia is not a serious issue in the ongoing PIII trials.